Publications by authors named "Laura Gerard"
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.
Purpose: Alkylating agents (ALKY) are the main chemotherapies used for advanced neuroendocrine tumors (NETs). O-Methylguanine-DNA methyltransferase (MGMT) status, as proficient (p) or deficient (d), may predict the response to ALKY.
Patients And Methods: MGMT-NET (ClinicalTrials.
Neuropilin 2 (NRP2), a transmembrane non-tyrosine kinase receptor, has been described as a potential critical player in the tumourigenesis of several solid cancers and particularly in neuroendocrine neoplasms (NENs). A soluble form of NRP2 (sNRP2) has been previously described and corresponds to a truncated splice isoform. Its prognostic value has never been studied in NEN.
View Article and Find Full Text PDFArticle Synopsis
- Glucagonoma is a rare type of pancreatic tumor, where the study focused on understanding how it's diagnosed, treated, and the overall outcomes for patients.
- A total of 38 cases were reviewed, revealing symptoms like necrolytic migratory erythema, weight loss, and diabetes; surgery was performed in most cases, showing high success rates in symptom relief.
- The research found that patients generally had a good survival rate (median 17.3 years), and treatments such as chemotherapy and targeted therapies were effective in managing the disease.
Article Synopsis
- The case discusses a patient with metastatic pancreatic neuroendocrine carcinoma and Cushing's syndrome, treated through five lines of therapy including various drug combinations and supportive treatments.* -
- Changes in circulating-free DNA (cfDNA) were analyzed during treatment, showing a strong correlation with disease progression and possibly serving as a predictive or early response marker.* -
- An increase in atypical circulating cells was observed as the disease progressed, alongside the cfDNA changes, providing insights into the patient's treatment response and tumor burden.*
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEPNEC) are characterized by a heterogeneous molecular profile and a poor prognosis. Circulating tumour DNA (ctDNA) analysis may be useful for NEC management. This study aimed at describing ctDNA mutations, to assess their predictive value for response to chemotherapies, and their change according to disease progression.
View Article and Find Full Text PDFBackground: The treatment of metastatic colorectal cancer (mCRC) relies of chemotherapy. The efficacy of the standard FOLFIRI-therapy could be improved by a modification of the regimen by splitting the dose of irinotecan on day 1 and day 3 in the FOLFIRI3 regimen.
Aim: To determine safety and efficacy of FOLFIRI3 regimen.
Background: The term loyalty can be defined as the attachment that characterises someone who consistent in their feelings, affections, or habits. By introducing the Declaration of General Practitioner (or preferred doctor declaration) in 2004, France adopted a formal incentive for patients to be faithful to their doctor since it entailed optimal coverage of medical care by their national health insurance There has been no research evaluating the impact of this measure and to determine the components of doctor-patient loyalty.
Aim: To explore what builds and maintains patients' loyalty to their GP.
Background: Bacteremia due to Pseudomonas aeruginosa is associated with grave clinical outcomes. Recent studies have emphasized the importance of appropriate empirical therapy, but controversy arises when piperacillin-tazobactam is used against isolates with reduced susceptibility.
Methods: We performed a retrospective cohort study of pseudomonal bacteremia from 2002 to 2006.
Objective: To assess the prevalence of diarrhea at a university-affiliated medical center and the presence of modifiable risk factors.
Methods: A point prevalence survey was conducted. All patients hospitalized for more than 24 hours were asked if they were experiencing diarrhea.
An integrated pharmacoeconomic approach to antimicrobial formulary decision-making.
Am J Health Syst Pharm
April 2006
Purpose: The utility of a novel interdisciplinary approach to antimicrobial formulary decision-making was studied.
Methods: Pseudomonas aeruginosa minimum inhibitory concentration (MIC) distribution data for cefepime and ceftazidime were retrieved from nonrepeat isolates obtained from November 2002 to October 2003. Unbound drug exposures were simulated for 5000 patients using the Monte Carlo method.
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Expert Rev Anti Infect Ther
April 2005
Rifaximin is a poorly water-soluble and minimally absorbed (<0.4%) rifamycin with in vitro activity against enteric Gram-negative bacteria including enteric pathogens. Fecal levels of the drug after 3 days' oral therapy exceed 8000 microg/g.
View Article and Find Full Text PDF